Troubleshooting heparin resistance DOI
Cheryl L. Maier, Jean M. Connors, Jerrold H. Levy

et al.

Hematology, Journal Year: 2024, Volume and Issue: 2024(1), P. 186 - 191

Published: Nov. 25, 2024

Abstract The term heparin resistance is likely best defined as the failure of an appropriate dose unfractionated (UFH) to achieve a predetermined level anticoagulation. Unfortunately, and despite many prior reports, there no established consensus what either or should be. Traditionally, assays used monitor anticoagulation with UFH have been clot based, including activated partial thromboplastin time, for patients on ward intensive care unit, clotting undergoing vascular interventions cardiopulmonary bypass. these tests may be highly influenced by other factors occurring in patients, especially those inflammation acute infection, noted during COVID-19 pandemic. Many hospitals thus moved anti-Xa testing monitoring. Another important factor defining includes dosing, whether weight-based total daily dosing used, initial reports described doses independent body weight. Multiple causes apparent include hypercoagulability, antithrombin deficiency, andexanet alfa direct oral anticoagulant reversal, thrombocytosis, antiphospholipid antibody syndromes. Treatment options managing administration additional UFH, supplementation, use alternative such thrombin inhibitors bivalirudin argatroban.

Language: Английский

Post-Recovery Mental Health Outcomes in Young Adults with Mild-to-Moderate COVID-19: A Cross-Sectional Study DOI Creative Commons
Ashkan Latifi

COVID, Journal Year: 2025, Volume and Issue: 5(2), P. 27 - 27

Published: Feb. 19, 2025

Background: The long-term effects of COVID-19 infection represent an emerging area research that explores the relationships between a history and its consequential sequelae. This study investigates potential associations among time since infection, severity acute phase disease, sex, while controlling for age, in relation to mental health. Methods: A total 305 university students participated this cross-sectional study, during which data were collected using SCL-90-R questionnaire. analysis was conducted MANCOVA, ANCOVA, partial Kendall’s Tau methods. Results: findings indicated factors such as sex—specifically being female—longer elapsed disease significantly influenced multiple scales SCL-90-R. Conclusions: Based on these findings, it is recommended investigations into health issues consider biological severity, risk young adults with infection.

Language: Английский

Citations

0
A safety comparison of heparin and argatroban anticoagulation in veno‐venous extracorporeal membrane oxygenation with a focus on bleeding DOI Creative Commons
Filip Burša, Jan Máca,

Jiří Sagan

et al.

Transfusion Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 7, 2024

Abstract Background Anticoagulation during extracorporeal membrane oxygenation (ECMO) might still lead to severe bleeding complications. Heparin is the most frequently used anticoagulant, but novel drugs could be promising. Argatroban a new alternative heparin. To date, no robust studies have confirmed clear superiority of argatroban (AG) over heparin, although it has some advantages and may safer. Study Design Methods An observational study was conducted in all adult veno‐venous ECMO patients with COVID‐19‐associated acute respiratory distress syndrome admitted University Hospital Ostrava ( n = 63). They were anticoagulated heparin first period AG second period, targeting same activated partial thromboplastin time (aPTT; 45–60 s). Bleeding complications requiring transfusion life‐threatening events evaluated. The primary objective compare terms bleeding, requirements mortality‐related bleeding. Results total on per patient 16 days an in‐hospital mortality 55.6%. red blood cell consumption group (median 2.7 transfusions/week) significantly lower than 4.2 transfusions/week, p 0.011). Life‐threatening higher compared (35.7% vs. 10.2%, 0.035 ), also (21.4% 2.0%, 0.032). Discussion interesting less need for transfusions improved safety

Language: Английский

Citations

1
“Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned?” Comment from Wada et al DOI
Hideo Wada, Takeshi Matsumoto, Katsuya Shiraki

et al.

Journal of Thrombosis and Haemostasis, Journal Year: 2024, Volume and Issue: 22(12), P. 3647 - 3649

Published: Nov. 28, 2024

Language: Английский

Citations

1
Decreased Protein C Pathway Activity in COVID-19 Compared to Non-COVID Sepsis: An Observational and Comparative Cohort Study DOI Creative Commons
Heiko Rühl, Christian Bode, Tobias Becher

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(9), P. 1982 - 1982

Published: Sept. 2, 2024

Sepsis-associated coagulopathy increases risk of mortality. Impairment the anticoagulant protein C (PC) pathway may contribute to thrombotic phenotype in coronavirus disease 2019 (COVID-19) sepsis. This study assessed functionality this COVID-19 and non-COVID sepsis by measuring its key enzymes, thrombin activated PC (APC). The population included 30 patients with COVID-19, 47 sepsis, 40 healthy controls. In controls, coagulation activation subsequent APC formation was induced 15 µg/kg recombinant factor VII one hour before blood sampling. plasma were measured using oligonucleotide-based enzyme capture assays. indirect markers prothrombin-fragment 1+2 (F1+2) thrombin-antithrombin complex (TAT) also measured. Compared stimulated median thrombin, F1+2, TAT levels higher (up 6-fold, p < 2 × 10−6) 4.7-fold, 0.010). 2.4-fold (7.44 pmol/L, = 0.011) 3.4-fold (10.45 10−4) than controls (3.08 pmol/L). Thrombin showed correlation both (r 0.364–0.661) 0.535–0.711). After adjustment for levels, APC/thrombin, APC/F1+2, APC/TAT ratios 2-fold (p 0.036), 6-fold 3 10−7) 3-fold 8 lower group group, latter two conclusion, it found that a comparatively response as compared patients, potentially linked endothelial dysfunction, contributes prothrombotic

Language: Английский

Citations

0
Reply to the comments on “Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned?” from Wada et al. DOI
Toshiaki Iba, Jerrold H. Levy

Journal of Thrombosis and Haemostasis, Journal Year: 2024, Volume and Issue: 22(12), P. 3645 - 3646

Published: Nov. 28, 2024

Language: Английский

Citations

0
Troubleshooting heparin resistance DOI
Cheryl L. Maier, Jean M. Connors, Jerrold H. Levy

et al.

Hematology, Journal Year: 2024, Volume and Issue: 2024(1), P. 186 - 191

Published: Nov. 25, 2024

Abstract The term heparin resistance is likely best defined as the failure of an appropriate dose unfractionated (UFH) to achieve a predetermined level anticoagulation. Unfortunately, and despite many prior reports, there no established consensus what either or should be. Traditionally, assays used monitor anticoagulation with UFH have been clot based, including activated partial thromboplastin time, for patients on ward intensive care unit, clotting undergoing vascular interventions cardiopulmonary bypass. these tests may be highly influenced by other factors occurring in patients, especially those inflammation acute infection, noted during COVID-19 pandemic. Many hospitals thus moved anti-Xa testing monitoring. Another important factor defining includes dosing, whether weight-based total daily dosing used, initial reports described doses independent body weight. Multiple causes apparent include hypercoagulability, antithrombin deficiency, andexanet alfa direct oral anticoagulant reversal, thrombocytosis, antiphospholipid antibody syndromes. Treatment options managing administration additional UFH, supplementation, use alternative such thrombin inhibitors bivalirudin argatroban.

Language: Английский

Citations

0